Industry Alliance Program
To Change Medicine Right now.
CIRM established the Industry Alliance Program (IAP) as a direct opportunity for the industry to partner with CIRM in accelerating the most promising stem cell, gene and regenerative medicine therapy programs to commercialization. Through the IAP, CIRM is a dedicated and proactive partner to industry and CIRM grantees.
ACCESSPortfolio insight and engagement opportunties
Curated Portfolio AccessUpon identifying the IAP partner’s strategic focus areas the BD team will curate non-confidential information on relevant portfolio projects. CIRM will also provide relevant portfolio updates to the IAP partner on a regular basis.
Rapid ConnectionsCIRM’s active award management model fosters strong relationships with CIRM-funded PIs and companies. The BD team leverages these relationships to facilitate rapid and meaningful interactions between IAP partners and CIRM-funded PIs and companies.
REVIEWStreamlined diligence process
Streamlined OTL InteractionsCIRM has fostered working relationships with OTLs of major California academic institutions to increase awareness of CIRM-funded assets and ensure productive interactions for IAP partners. This results in efficient execution of CDAs, data room access, licensing negotiations, etc.
Efficient Due DiligenceThe BD team leverages internal project information, CIRM staff expertise and working relationships with project teams to assist in assembly of well-organized and thorough data packages for IAP partner review.
PARTNERClear pathway to commercialization
Better Informed NegotiationsCIRM provides advice, as needed, to both IAP partners and CIRM grantees on overall agreement structure, financial terms as well as the role of post-agreement CIRM funding.
Expert Guidance on CIRM RegulationsCIRM’s BD and legal teams advise both IAP partners and CIRM grantees on navigating relevant CIRM regulations and ensuring compliance in any partnering agreements.
Contact Us To
Learn More Today
Shyam Patel, Ph.D.,
Director, Business Development